Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD

This article was originally published in The Pink Sheet Daily

Executive Summary

British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.

You may also be interested in...



Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market

In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications

Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market

In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications

Shire Takes The Route Of Least Resistance Into Europe With Approved Oral ADHD Drug

Specialty pharma withdraws marketing application for Noven’s Daytrana patch after regulators request European study, sticks with in-licensed oral drug that’s already approved.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel